Product Description
An orally bioavailable, small-molecule, dihydrogen phosphate prodrug of the pyrazoloquinazoline Aurora kinase inhibitor AZD1152-hydroxyquinazoline pyrazol anilide (AZD1152-HQPA) with potential antineoplastic activity. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/barasertib)
Mechanisms of Action: AURK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 2: Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma
Phase 1: Acute Myeloid Leukemia|Leukemia|Other|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AZD1152 in diffuse large B-cell lymphoma | P2 |
Completed |
Diffuse Large B-Cell Lymphoma |
2013-09-09 |
|
| ORH/PID/6265 | P2 |
Completed |
Diffuse Large B-Cell Lymphoma |
2013-09-01 |
|
| 2009-010114-30 | P2 |
Terminated |
Acute Myeloid Leukemia |
2012-04-26 |
|
| SPARK-AML1 | P3 |
Completed |
Acute Myeloid Leukemia |
2011-06-01 |